None listed
Conditions
Interventions
Intervention1: MARS Depigmentation Serum: 2 3 drops of the depigmenting serum will be applied to the face and neck twice daily (morning and evening) and gently spread evenly over the skin.
Control Int
Sponsors
MARS Cosmetics Research & Development
Eligibility
Inclusion criteria
Inclusion criteria: 1. Female trial participants aged between 18-45 years (both ages inclusive). 2. Trial participants with mild to moderate post-acne scars (PIH), sunspots, age spots, dark spots, hyperpigmentation, blemishes, and/or enlarged pores on the face, as evaluated by the dermatologist using the Uneven Skin Tone Scale (0 9). 3. Approximately 25 percentage of the enrolled trial participants should have mild melasma, defined by an IGA score of 1. 4. Trial participants with general good health, as determined from a recent medical history, general physical examination, dermatological assessment. 5. Trial participants with normal to dry skin as determined by the general health screening form. 6. Trial participants with Fitzpatrick phototype III, IV and V as confirmed by general health screening form.
Exclusion criteria
Exclusion criteria: 1. Trial participants who are pregnant/ nursing or have plans of becoming pregnant during the study (self-declared). 2. Trial participants taking part in another study liable to interfere with this study. 3. Trial participants with known history or present condition of an allergic response to any cosmetic product. 4. Trial participants with any other signs of significant skin irritation or skin disease or currently taking any medication, which the Investigator believes may influence the interpretation of the data. 5. Trial participant who have undergone any facial treatments in past 4 weeks. 6. Trial participants who are on oral medications like topical or systemic corticosteroids, anti-fungal, or antibiotics or any prolonged use of steroidal anti-inflammatory, or anti-histaminic within 2 weeks prior to the study, undergoing any chemical treatment-facial / bleach / waxing / which will compromise the study. 7. Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness. 8. Employees of the CRO or the Sponsor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Reduction in skin blemishes, melasma, pores and improvement in skin texture after test product usage, assessed by dermatological evaluation 2. Reduction in pigmentation, pore size and improvement in skin texture and evenness after test product usage, analyzed by 3D Antera imaging 3. Reduction in pigmentation after test product usage, measured by SpectrophotometerTimepoint: Day 0, Day 14, Day 28, Day 56 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Visual documentation of changes in pigmentation and improvement in skin tone through VISIA CR imaging. 2. Participant-reported outcomes on perceived improvement in skin appearance, as captured through structured self-assessment questionnaires 3. Safety and tolerability of the test product throughout the study duration.Timepoint: Day 0, Day 14, Day 28, Day 56 | — |
Countries
India
Contacts
Public ContactSudhanthiran S
MS Clinical Research Pvt. Ltd
Outcome results
None listed